<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02123485</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-509-12</org_study_id>
    <nct_id>NCT02123485</nct_id>
  </id_info>
  <brief_title>The Antidepressive Effect of rTMS as add-on to ECT</brief_title>
  <acronym>TMS</acronym>
  <official_title>The Antidepressant Efficacy of Repetitive Transcranial Magnetic Stimulation ( rTMS) as add-on to Electroconvulsive Therapy (ECT). A Double Blind Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to investigate in which degree low frequency right prefrontal&#xD;
      rTMS used ad add-on may potentiate the antidepressant effect of unilateral ECT and accelerate&#xD;
      remission .&#xD;
&#xD;
      To investigate the correlation between blood concentration of specific inflammation makers&#xD;
      and change in depressive symptoms during treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ECT is a well-established and effective method for the treatment of severe depression. During&#xD;
      the last decades, rTMS has appeared as a potential new non-invasive antidepressant method,&#xD;
      which may be a potential alternative to ECT due to fewer side effects.&#xD;
&#xD;
      Both methods expose the brain to an electric current. But while ECT is associated with global&#xD;
      cerebral stimulation elicited by an epileptic seizure, rTMS implies non-convulsive focal&#xD;
      stimulation through a time varying magnetic field. Thus, the antidepressant effect of rTMS&#xD;
      does not depend on seizure activity and consequently requires no anesthesia. In addition,&#xD;
      rTMS seems not to be associated with cognitive disturbances.&#xD;
&#xD;
      Previous research indicates that the antidepressant effect of rTMS is associated with&#xD;
      specific stimulation of the dorsolateral prefrontal cortex. The majority of clinically&#xD;
      controlled studies have used high frequency stimulation of the left frontal cortex (1-4). Few&#xD;
      have used right prefrontal low frequency rTMS, which has less side effects, such as local&#xD;
      discomfort and a lower risk of releasing epileptic seizures, than high frequency stimulation&#xD;
      (5-10). Both models have been used with varying results. Meta-analysis of the antidepressant&#xD;
      effect of rTMS (11,x) have found a modest, statistically significant antidepressant effect&#xD;
      but generally definite conclusions on the antidepressant effect of rTMS has been difficult to&#xD;
      draw, probably because of small and selected study populations, varying ways of stimulation&#xD;
      and other confounding factors in the clinical setting.&#xD;
&#xD;
      The important clinical question of whether rTMS may substitute ECT in the treatment of&#xD;
      depression has almost exclusively been elucidated in studies using high frequency stimulation&#xD;
      of the left frontal cortex. Some of these suggest that the effectiveness of rTMS is equal to&#xD;
      that of ECT in non-delusional patients (12-19). However, a recent investigation has compared&#xD;
      the antidepressant efficacy and side effects of right prefrontal low frequency rTMS with ECT.&#xD;
      In this study the mean Hamilton total 17-item (HAM-D score) scores were reduced significantly&#xD;
      over time in both groups (ECT: p&lt;0.001, rTMS: p&lt;0.001); but ECT was more effective than rTMS&#xD;
      on a short term after 3 weeks of treatment. The outcome did not point to right frontal low&#xD;
      frequency rTMS as a first line substitute for ECT, but it might have place in the treatment&#xD;
      of depression as add on to other types of treatment.&#xD;
&#xD;
      ECT is normally administered 3 times a week for 3-4 weeks. Daily treatment sessions might&#xD;
      accelerate remission, but is impossible because of cognitive side effects. However, rTMS&#xD;
      seems not to be associated with reduction in cognitive performance and might potentiate the&#xD;
      antidepressant efficacy of ECT. Therefore the investigators have found it clinical&#xD;
      interesting to investigate in which degree low frequency right prefrontal rTMS used ad add-on&#xD;
      may potentiate the antidepressant effect of unilateral ECT and accelerate remission .&#xD;
&#xD;
      In addition we want to investigate te correlation between change in depressive symptoms and&#xD;
&#xD;
      -blood concentration of specific inflammation CNS- makers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruiting of patients difficult combined by lack of money&#xD;
  </why_stopped>
  <start_date type="Actual">April 1, 2015</start_date>
  <completion_date type="Actual">July 1, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission</measure>
    <time_frame>7 weeks</time_frame>
    <description>The Hamilton (17 -item) Rating Scale for Depression is a clinician-administered assessement scale, that contains 17 items pertaining to symptoms of depression experienced over the past week. The total range is 0-52.Higher scores mean a worse outcomeRemission is defined by a Hamilton 17-item total score &lt; 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>7 weeks</time_frame>
    <description>The Hamilton (17 -item) Rating Scale for Depression is a clinician-administered assessement scale, that contains 17 items pertaining to symptoms of depression experienced over the past week. The total range is 0-52.Higher scores mean a worse outcome. Response is defined by a reduction in the Hamilton 17 item score of &gt;= 50%</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>low frequency rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham-rTMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham right prefrontal rTMS 2 times a week</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low frequency (1 hz) rTMS, as add-on to ECT</intervention_name>
    <description>Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.</description>
    <arm_group_label>low frequency rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham-rTMS</intervention_name>
    <description>Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.</description>
    <arm_group_label>Sham-rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients admitted to the Psychiatric Hospital of Aarhus&#xD;
&#xD;
          -  Patients referred for ECT&#xD;
&#xD;
          -  Age 18-80 years&#xD;
&#xD;
          -  Moderate or severely depressed patients (ICD-10(DSM-IV)&#xD;
&#xD;
          -  HAM-D score (17-item) ≥20 and/or Ham-D subscale ≥10.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Organic brain disease&#xD;
&#xD;
          -  Epilepsy or disposition to epilepsy&#xD;
&#xD;
          -  Metallic objects in chest or brain&#xD;
&#xD;
          -  Cardiac pacemaker&#xD;
&#xD;
          -  Somatic diseases associated with brain dysfunction&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Severe agitation or delirium&#xD;
&#xD;
          -  Alcohol or drug dependence (ICD-10)&#xD;
&#xD;
          -  Use of coercive measures&#xD;
&#xD;
          -  The patient does not wish to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Poul Erik Buchholtz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poul Erik Buchholtz, MD Telephone: 004578472109 Email: poulhans@rm.dk</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital, Risskov</name>
      <address>
        <city>Aarhus</city>
        <state>Risskov</state>
        <zip>8240</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 13, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2014</study_first_posted>
  <results_first_submitted>November 12, 2020</results_first_submitted>
  <results_first_submitted_qc>February 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2021</results_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Poul Erik Buchholtz</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Depression,</keyword>
  <keyword>ECT,</keyword>
  <keyword>rTMS,</keyword>
  <keyword>Right prefrontal,</keyword>
  <keyword>antidepressive efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 13, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02123485/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Right Prefrontal Low Frequency (1 hz) Repetitive Transcranial Magnetic Stimulation (rTMS)</title>
          <description>Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week&#xD;
Low frequency (1 hz) rTMS, as add-on to ECT: Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.</description>
        </group>
        <group group_id="P2">
          <title>Sham- Right Prefrontal Low Frequency (1 hz) Repetitive Transcranial Magnetic Stimulation (rTMS)</title>
          <description>Sham right prefrontal rTMS 2 times a week&#xD;
Sham-rTMS: Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Frequency Repetitive Transcranial Magnetic Stimulation (rTMS)</title>
          <description>Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week&#xD;
Low frequency (1 hz) rTMS, as add-on to ECT: Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.</description>
        </group>
        <group group_id="B2">
          <title>Sham-rTMS</title>
          <description>Sham right prefrontal rTMS 2 times a week&#xD;
Sham-rTMS: Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="19" upper_limit="80"/>
                    <measurement group_id="B2" value="47" lower_limit="21" upper_limit="79"/>
                    <measurement group_id="B3" value="49" lower_limit="19" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton depression scale score</title>
          <description>The Hamilton (17 -item) Rating Scale for Depression is a clinician-administered assessement scale, that contains 17 items pertaining to symptoms of depression experienced over the past week. Full range = 0-52.&#xD;
The Hamilton 6-item subscale coveres 6 core symptoms of the 17 items. Full range = 0-22&#xD;
The major depression inventory scale is a self-reported modd questionnaire which is able to generate an estimate of symptom severety. The scale coveres 10 items. Full range =0-50 Increasing scores correlate to increasing severity of depression on all of the above mentioned scores.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Hamilton depression rating scale (17-item)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="14" upper_limit="30"/>
                    <measurement group_id="B2" value="26" lower_limit="19" upper_limit="37"/>
                    <measurement group_id="B3" value="25" lower_limit="14" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hamilton depression rating scale (6-item)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13" lower_limit="8" upper_limit="16"/>
                    <measurement group_id="B2" value="13" lower_limit="10" upper_limit="17"/>
                    <measurement group_id="B3" value="13" lower_limit="8" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Depression inventory</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="31" upper_limit="50"/>
                    <measurement group_id="B2" value="41" lower_limit="30" upper_limit="50"/>
                    <measurement group_id="B3" value="43" lower_limit="30" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of patients with Severe depression</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>number of patients with bipolar depressive</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>number of patients with melancholic depression</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>number of patients with psychotic depression</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antidepressant drug treatment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission</title>
        <description>The Hamilton (17 -item) Rating Scale for Depression is a clinician-administered assessement scale, that contains 17 items pertaining to symptoms of depression experienced over the past week. The total range is 0-52.Higher scores mean a worse outcomeRemission is defined by a Hamilton 17-item total score &lt; 8.</description>
        <time_frame>7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Frequency rTMS</title>
            <description>Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week&#xD;
Low frequency (1 hz) rTMS, as add-on to ECT: Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.</description>
          </group>
          <group group_id="O2">
            <title>Sham-rTMS</title>
            <description>Sham right prefrontal rTMS 2 times a week&#xD;
Sham-rTMS: Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission</title>
          <description>The Hamilton (17 -item) Rating Scale for Depression is a clinician-administered assessement scale, that contains 17 items pertaining to symptoms of depression experienced over the past week. The total range is 0-52.Higher scores mean a worse outcomeRemission is defined by a Hamilton 17-item total score &lt; 8.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response</title>
        <description>The Hamilton (17 -item) Rating Scale for Depression is a clinician-administered assessement scale, that contains 17 items pertaining to symptoms of depression experienced over the past week. The total range is 0-52.Higher scores mean a worse outcome. Response is defined by a reduction in the Hamilton 17 item score of &gt;= 50%</description>
        <time_frame>7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Frequency rTMS</title>
            <description>Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week&#xD;
Low frequency (1 hz) rTMS, as add-on to ECT: Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.</description>
          </group>
          <group group_id="O2">
            <title>Sham-rTMS</title>
            <description>Sham right prefrontal rTMS 2 times a week&#xD;
Sham-rTMS: Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.</description>
          </group>
        </group_list>
        <measure>
          <title>Response</title>
          <description>The Hamilton (17 -item) Rating Scale for Depression is a clinician-administered assessement scale, that contains 17 items pertaining to symptoms of depression experienced over the past week. The total range is 0-52.Higher scores mean a worse outcome. Response is defined by a reduction in the Hamilton 17 item score of &gt;= 50%</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 weeks</time_frame>
      <desc>All-Cause Mortality monitored/assessed in all participants who completed the study. Serious and Other adverse events were monitored/assessed in 26 participants (74% of the population).</desc>
      <group_list>
        <group group_id="E1">
          <title>Low Frequency rTMS</title>
          <description>Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week&#xD;
Low frequency (1 hz) rTMS, as add-on to ECT: Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.</description>
        </group>
        <group group_id="E2">
          <title>Sham-rTMS</title>
          <description>Sham right prefrontal rTMS 2 times a week&#xD;
Sham-rTMS: Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>severe confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>mild headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>mild discomfort during treatment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study is under-powered</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Poul Erik Buchholtz</name_or_title>
      <organization>Department of Affective Disorder, Aarhus University Hospital, Denmark</organization>
      <phone>21474299</phone>
      <email>Buchholtz.Hansen@ps.rm.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

